ACHE and Alzheimer disease: While AChE levels in the AD brain are significantly reduced, BChE levels are increased, particularly in the entorhinal and inferotemporal cortex,5, 8 leading to the suggestion that increase in BChE expression particularly in the orbitofrontal cortex could be used as a sensitive and specific biomarker for AD.7